Cadex Genomics
Cadex Genomics: Pioneering personalized cancer treatment through advanced molecular diagnostic tests.
Founded
2018Cadex Genomics: Pioneering personalized cancer treatment through advanced molecular diagnostic tests.
Cadex Genomics, founded with a mission to enhance the lives of cancer patients, focuses on developing innovative molecular diagnostic tests. The company specializes in liquid-based technology to provide personalized insights into cancer therapy responses. Their flagship product, Alibrex®, is a blood test designed to identify real-time disease progression in stage IV cancer patients, aiming for availability by late 2024 or early 2025. Cadex Genomics seeks to revolutionize cancer treatment by significantly reducing the time it takes for oncologists to evaluate treatment efficacy.
Notable figures affiliated with Cadex Genomics include experts in molecular diagnostics and oncology, although specific names are not provided. The company has garnered attention for its cutting-edge approach to cancer diagnostics, combining proven DNA measurement techniques with advanced technology to improve accuracy and sensitivity. By offering timely and precise diagnostic tools, Cadex Genomics aims to make a substantial impact on cancer treatment outcomes and patient quality of life.
Companies similar to Cadex Genomics include Liquid Genomics, Circulogene Theranostics, Biodesix and Adela.
Cadex Genomics was founded in 2018.
Cadex Genomics' headquarters is located in Redwood City, CA, US.
Cadex Genomics' most recent funding round was for $1.5M (USD) in February 2019.
As of Feb 15, 2019, Cadex Genomics has disclosed funding of $1.5M (USD). Undisclosed round amounts are excluded.
Cadex Genomics has 7 employees as of Feb 4, 2024.
Adela
adelabio.com
